2025
Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study
Zaki N, Chen L, Lane R, Doherty T, Drevets W, Morrison R, Sanacora G, Wilkinson S, Young A, Lacerda A, Paik J, Popova V, Fu D. Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study. The International Journal Of Neuropsychopharmacology 2025, 28: pyaf027. PMID: 40319349, PMCID: PMC12143125, DOI: 10.1093/ijnp/pyaf027.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionSustained 3Oral antidepressantNon-treatment-resistant major depressive disorderMontgomery-Asberg Depression Rating ScaleTreatment-resistant depression treatmentEsketamine nasal sprayDepression Rating ScaleMajor depressive disorderLong-term extension studySafety of esketamineLong-term safetyRate of relapseMontgomery-AsbergDepressive disorderDepression severityEsketamine dosesExtension studySuicide riskDepressive symptomsEsketamineRating ScaleMaintenance treatmentAdverse eventsLong-term treatmentDoes BMI matter when treating depression with esketamine? A retrospective analysis of real-world data
Ansari M, Rhee T, Santucci M, Nikayin S. Does BMI matter when treating depression with esketamine? A retrospective analysis of real-world data. Journal Of Affective Disorders 2025, 381: 22-28. PMID: 40185405, DOI: 10.1016/j.jad.2025.03.198.Peer-Reviewed Original ResearchConceptsResponse to treatmentEsketamine treatmentFactors associated with response to treatmentRetrospective analysisMontgomery-Asberg Depression Rating ScaleNon-obese patientsTreatment-resistant depressionDepression Rating ScaleRetrospective analysis of real-world dataIncreased body fatIntranasal esketamineMontgomery-AsbergTreatment responseEsketaminePrimary outcomeActive metaboliteBMIBody fatPatientsTreating depressionRating ScaleContinuous variablesIntranasalTreatmentObesity
2024
Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic
Back A, Freeman-Young T, Morgan L, Sethi T, Baker K, Myers S, McGregor B, Harvey K, Tai M, Kollefrath A, Thomas B, Sorta D, Kaelen M, Kelmendi B, Gooley T. Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic. JAMA Network Open 2024, 7: e2449026. PMID: 39636638, PMCID: PMC11621983, DOI: 10.1001/jamanetworkopen.2024.49026.Peer-Reviewed Original ResearchConceptsAdvanced practice practitionersSymptoms of depressionMontgomery-Asberg Depression Rating ScalePosttraumatic stress disorderSymptoms of burnoutMontgomery-Asberg Depression Rating Scale scoreSymptoms of posttraumatic stress disorderFrontline carePsilocybin therapyRandomized clinical trialsSevere symptoms of depressionMental health diagnosesScore changesImprove symptoms of depressionCOVID-19 pandemicPCL-5Intention-to-treat principleMedication sessionsDepression Rating ScalePCL-5 scoresPsychological morbidityHealth diagnosisMain OutcomesPractice practitionersUS cliniciansEfficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial.
Fava M, Stahl S, Pani L, De Martin S, Cutler A, Maletic V, Gorodetzky C, Vocci F, Sapienza F, Kosten T, Kröger C, Champasa P, O'Gorman C, Guidetti C, Alimonti A, Comai S, Mattarei A, Folli F, Bushnell D, Traversa S, Inturrisi C, Manfredi P, Pappagallo M. Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial. The Journal Of Clinical Psychiatry 2024, 85 PMID: 38917366, DOI: 10.4088/jcp.24m15265.Peer-Reviewed Original ResearchConceptsMontgomery-Asberg Depression Rating ScaleIntent-to-treatIntent-to-treat analysisStandard antidepressantsDepressive disorderPost Hoc AnalysisBaseline Montgomery-Asberg Depression Rating ScaleInadequate response to standard antidepressantsSevere depressionPost hoc analysis of patientsDepression Rating ScaleMajor depressive disorderAnalysis of patientsAdverse eventsMontgomery-AsbergConsistent with prior studiesPlacebo-controlled trialRating ScaleEfficacy measuresPer-protocolIntent-to-treat populationTreatment adherencePhase 3 randomized controlled trialsAdjunctive treatmentMDD
2023
Association between perceived stress and brain structure volumes in older adults without late-life depression: a key role for the thalamus?
Anam A, Wang L, Pearlson G. Association between perceived stress and brain structure volumes in older adults without late-life depression: a key role for the thalamus? American Journal Of Geriatric Psychiatry 2023, 31: s61-s62. DOI: 10.1016/j.jagp.2022.12.221.Peer-Reviewed Original ResearchLate-life depressionThalamus volumeEarly life stressHC groupLLD groupPrefrontal cortexOlder adultsAnterior cingulateBrain volumeControl groupDuke Depression Evaluation ScheduleMontgomery-Asberg Depression Rating ScaleSimilar findingsHealthy control subjectsDepression Rating ScaleIntracranial brain volumeSignificant differencesSignificant correlationConnecticut Health CenterDorsal anterior cingulateSubcortical brain regionsStandardized acquisition protocolBrain structure volumesVentral anterior cingulateInstitutional review boardRegistered clinical trials investigating ketamine and esketamine for treatment-resistant depression: A systematic review
Brendle M, Ragnhildstveit A, Slayton M, Smart L, Cunningham S, Zimmerman M, Seli P, Gaffrey M, Averill L, Robison R. Registered clinical trials investigating ketamine and esketamine for treatment-resistant depression: A systematic review. Journal Of Psychedelic Studies 2023, 6: 176-187. DOI: 10.1556/2054.2022.00234.Peer-Reviewed Original ResearchTreatment-resistant depressionMontgomery-Asberg Depression Rating ScaleDepression Rating ScaleLate-phase trialsTrial eligibilityPatient characteristicsDrug regimensClinical outcomesResults databaseRegistered trialsClinical trialsTreatment responseEsketaminePharmacological approachesPRISMA guidelinesCombination treatmentMost trialsClinical practiceElectronic registryKetamineSystematic reviewFinal reviewTherapeutic useQualitative synthesisStudy design
2021
Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial
Wilkinson ST, Rhee TG, Joormann J, Webler R, Ortiz Lopez M, Kitay B, Fasula M, Elder C, Fenton L, Sanacora G. Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial. Psychotherapy And Psychosomatics 2021, 90: 318-327. PMID: 34186531, DOI: 10.1159/000517074.Peer-Reviewed Original ResearchConceptsTreatment-resistant depressionCognitive behavioral therapyAntidepressant effectsClinical trialsMontgomery-Asberg Depression Rating ScaleBehavioral therapyGreater sustained improvementsRapid-acting antidepressantsSubset of patientsDepression Rating ScaleTime interaction effectsEffect sizeKetamine respondersClinical responseIntravenous ketamineIntravenous infusionQuick InventoryOngoing treatmentSustained improvementCBT groupTreatment approachesLong-term exposureLarge effect sizesDepressive symptomatologyKetamine
2011
Adjunctive Risperidone Treatment for Antidepressant-Resistant Symptoms of Chronic Military Service–Related PTSD: A Randomized Trial
Krystal JH, Rosenheck RA, Cramer JA, Vessicchio JC, Jones KM, Vertrees JE, Horney RA, Huang GD, Stock C, Group F. Adjunctive Risperidone Treatment for Antidepressant-Resistant Symptoms of Chronic Military Service–Related PTSD: A Randomized Trial. JAMA 2011, 306: 493-502. PMID: 21813427, DOI: 10.1001/jama.2011.1080.Peer-Reviewed Original ResearchConceptsMilitary-related posttraumatic stress disorderMontgomery-Asberg Depression Rating ScalePosttraumatic stress disorderClinical Global Impression ScaleClinician-Administered PTSD ScaleHamilton Anxiety ScalePlacebo-controlled multicenter trialCAPS scoresSelf-reported weight gainSecond-generation antipsychotic risperidoneAdjunctive risperidone treatmentAntidepressant-resistant symptomsPrimary outcome measureChronic military-related posttraumatic stress disorderGlobal Impression ScaleOutpatient medical centerDepression Rating ScaleSymptoms of depressionQuality of lifePlacebo groupRisperidone groupVeterans RANDAdverse eventsOngoing symptomsMulticenter trial
2008
What Is the Biopsychosocial Role of Human Immunodeficiency Virus Positivity in Patients With End-Stage Liver Disease Who Undergo Orthotopic Liver Transplantation?
Silva V, Ferrara M, Mazzi F, Pingani L, Cocchi S, Romano A, Masetti M, Gerunda GE, Guaraldi G, Rigatelli M. What Is the Biopsychosocial Role of Human Immunodeficiency Virus Positivity in Patients With End-Stage Liver Disease Who Undergo Orthotopic Liver Transplantation? Transplantation Proceedings 2008, 40: 1910-1912. PMID: 18675086, DOI: 10.1016/j.transproceed.2008.05.060.Peer-Reviewed Original ResearchConceptsTransplant Evaluation Rating ScaleMontgomery-Asberg Depression Rating ScaleHuman immunodeficiency virusHIV groupHIV patientsPsychiatric comorbidityEnd-stage liver disease patientsHuman immunodeficiency virus (HIV) positivityEnd-stage liver diseaseAsberg Depression Rating ScaleConsultation-liaison psychiatry serviceRating ScaleBaseline psychiatric comorbidityLiver transplantation centerNon-HIV patientsOLT waiting listOrthotopic liver transplantationLiver disease patientsObservational prospective studySolid organ transplantationLiaison psychiatry serviceDepression Rating ScaleLiver transplantationTransplantation centersVirus positivity
2007
Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.
Robinson D, Gilmor M, Yang Y, Moonsammy G, Azzaro A, Oren D, Campbell B. Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials. Psychopharmacology Bulletin 2007, 40: 15-28. PMID: 18007565.Peer-Reviewed Original ResearchConceptsMontgomery-Asberg Depression Rating ScaleMajor depressive disorderDepression Rating ScaleHAM-D28Rating ScaleDepressive disorderEfficacy trialsIndividual symptomsTreatment effectsPlacebo-controlled efficacy trialTransdermal systemSelegiline transdermal systemEnd of treatmentHamilton Rating ScaleBeneficial therapeutic effectsMajor monoamine neurotransmittersMonoamine oxidase inhibitorsRandom-effects modelCore depression symptomsGenital symptomsMADRS itemsDrug therapySignificant treatment effectTherapeutic effectSpecific symptoms
2004
Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study
Nelson JC, Mazure CM, Jatlow PI, Bowers MB, Price LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biological Psychiatry 2004, 55: 296-300. PMID: 14744472, DOI: 10.1016/j.biopsych.2003.08.007.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic Uptake InhibitorsAdultAntidepressive Agents, Second-GenerationAntidepressive Agents, TricyclicChromatography, High Pressure LiquidDepressive DisorderDesipramineDouble-Blind MethodDrug Therapy, CombinationFemaleFluoxetineHumansMaleMiddle AgedNorepinephrinePsychiatric Status Rating ScalesSelective Serotonin Reuptake InhibitorsSerotoninTreatment OutcomeConceptsMontgomery-Asberg Depression Rating ScaleHamilton Depression Rating Scale scoresDepression Rating Scale scoresNonpsychotic unipolar major depressionPatient withdrew consentTreatment-resistant patientsWeeks of hospitalizationWeeks of treatmentCombination of fluoxetineOnset of actionAdequate plasma levelsDouble-blind conditionsDepression Rating ScaleTreatment of depressionRating Scale scoresUnipolar major depressionDrug plasma concentrationsDMI doseWithdrew consentAntidepressant medicationRandomized studyReuptake inhibitionSerotonergic agentsPlasma levelsMajor depression
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply